Vote Scores

Home / Companies / Amneal Pharmaceuticals, Inc. / 2 May 2024

Meeting · year to 30 June 2024256 filers reporting

Amneal Pharmaceuticals, Inc.: meeting of 2 May 2024

Votes reported on Form N-PX, item by item

256 Form N-PX filers reported votes at the Amneal Pharmaceuticals, Inc. meeting of 2 May 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

11 nominees; 93.3% of reported votes for; 57 filers withheld from or voted against at least one nominee.

2,134 vote records from 98 filers. 2 of the 97 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

96.9% for2.0% against1.0% other2.1% against management98 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

384 vote records from 254 filers. 9 of the 246 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

0 filers reported share counts too large to be the holding described. No share split is published for this item. How that is decided

92.9% for3.5% against3.5% other3.7% against management254 filers
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

194 vote records from 98 filers. 0 of the 97 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

99.0% for0.0% against1.0% other0.0% against management98 filers100.0% for0.0% against0.0% against management33,275,456 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalForForFor
State Street and SPDRForForFor
American CenturyForForFor
Franklin TempletonForForFor
InvescoForForFor
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForForFor
J.P. MorganNo reportForNo report
Goldman SachsForForFor
WisdomTreeAgainst *ForFor
PGIM and PrudentialForForFor
Jackson National fundsForForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceForForFor
ThriventForForFor
Lincoln FinancialForForFor
VoyaForForFor
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalForForFor
Brighthouse FundsForForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForForFor
BNY MellonAgainst *ForFor
PrincipalForForFor
Pacific Life fundsForForFor
Global XForForFor
MFSForForFor
Federated HermesForForFor
AllianceBernsteinNo reportForNo report
DWSForForFor
AllspringForForFor
VirtusForForFor
Janus HendersonNo reportForNo report
Neuberger BermanForForFor
American BeaconForForFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Amneal Pharmaceuticals, Inc. meeting?

256 Form N-PX filers reported votes at the meeting of 2 May 2024. On say-on-pay, 9 of 246 voted against management (3.7%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Amneal Pharmaceuticals, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Amneal Pharmaceuticals, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Amneal Pharmaceuticals, Inc. with a meeting date within three days of 2 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.